Gilead Sciences (GILD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Gilead has a market-leading portfolio of HIV treatments, and the company’s efforts to develop additional innovative HIV treatments are being appreciated by investors. With a market share of more ...

Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

The split-up of Galapagos is only the latest shake-up in the company in recent years. Other major events have included the ...

Livdelzi's approval and strong market potential, combined with Gilead's robust HIV portfolio, position the company for significant revenue growth. Despite competition and debt, Gilead's financial ...

providing valuable ballast to Gilead's portfolio. Earlier this year, Gilead acquired the liver disease-focused biotech Cyma Bay in a deal worth ~$4.3bn, giving it access to seladelpar, now ...

Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseases. While the drug candidates ...